Potential role of P4HB in the tumor microenvironment and its clinical prognostic value: a comprehensive pan-cancer analysis and experimental validation with a focus on KIRC

被引：1

作者：

Zhang, Linxue ^{[1
]}

Li, Yu-wei ^{[2
]}

Xie, Tianyi ^{[3
]}

Sun, Ke ^{[1
]}

Huang, Xiang ^{[4
]}

Xiong, Wei ^{[4
]}

Liu, Rui-ji ^{[4
]}

机构：

[1] Univ Elect Sci & Technol China, Sch Mat & Energy, Chengdu 610054, Peoples R China

[2] Univ Elect Sci & Technol China, Sch Med, Chengdu 610054, Sichuan, Peoples R China

[3] Univ Pittsburgh, Kenneth P Dietrich Sch Arts & Sci, Dept Neurosci, Pittsburgh, PA USA

[4] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sch Med, Dept Urol, Chengdu 610072, Peoples R China

来源：

CANCER CELL INTERNATIONAL | 2025年 / 25卷 / 01期

关键词：

P4HB; Pan-cancer; Tumor microenvironment; Kidney renal clear cell carcinoma; Immune checkpoint molecules; PROTEIN DISULFIDE-ISOMERASE; T-CELLS; EXPRESSION; SURVIVAL; REVEALS;

D O I：

10.1186/s12935-024-03575-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundTumor microenvironment (TME) plays a crucial role in tumor growth and metastasis. Exploring biomarkers that are significantly associated with TME can help guide individualized treatment of patients.MethodsWe analyzed the expression and survival of P4HB in pan-cancer through the TCGA database, and verified the protein level of P4HB by the HPA database. In addition, we used the Metascape database to construct protein-protein interaction networks and the single-cell Sequencing database for functional analysis. An immune cell infiltration analysis was performed to explore the potential role of P4HB in TME. We further analyze the relationship between P4HB and immune checkpoint molecules to explore the role of P4HB in immune checkpoint blockade therapy. Finally, the oncogenic role of P4HB in RCC cells was validated using colony formation and wound healing assays.ResultsRNA and protein levels of P4HB were extensively up-regulated in pan-cancer. However, high P4HB expression was associated with poor survival in KIRC. The clinical relevance analyses of P4HB suggested that high P4HB expression was associated with advanced clinical TNM stage. Moreover, multivariate cox regression analysis indicated that P4HB (HR = 1.372, 95% CI 1.047-1.681, P = 0.019) was an independent risk factor for OS in KIRC. Functional analysis revealed that P4HB is involved in hypoxia, TME and immune system processes. Our study also found that high P4HB expression was significantly correlated with elevated infiltration levels in CD8 + T cells and M2 macrophages. The results of colony formation and wound healing assays showed that knockdown of P4HB inhibited the RCC growth and migration.ConclusionsP4HB is a specific biomarker for KIRC prognosis and is significantly associated with clinical characteristics. In addition, P4HB may play an influential role in TME and is a biomarker for ICB therapy.

引用

页数：20

共 58 条

[1] Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL [J].

Anand, Praveen ;

Guillaumet-Adkins, Amy ;

Dimitrova, Valeriya ;

Yun, Huiyoung ;

Drier, Yotam ;

Sotudeh, Noori ;

Rogers, Anna ;

Ouseph, Madhu M. ;

Nair, Monica ;

Potdar, Sayalee ;

Isenhart, Randi ;

Kloeber, Jake A. ;

Vijaykumar, Tushara ;

Niu, Leili ;

Vincent, Tiffaney ;

Guo, Guangwu ;

Frede, Julia ;

Harris, Marian H. ;

Place, Andrew E. ;

Silverman, Lewis B. ;

Teachey, David T. ;

Lane, Andrew A. ;

DeAngelo, Daniel J. ;

Aster, Jon C. ;

Bernstein, Bradley E. ;

Lohr, Jens G. ;

Knoechel, Birgit .

BLOOD, 2021, 137 (18) :2463-2480

[2] Investigation of GPR143 as a promising novel marker for the progression of skin cutaneous melanoma through bioinformatic analyses and cell experiments [J].

Bai, Ruimin ;

Yin, Pan ;

Xing, Zixuan ;

Wu, Shaobo ;

Zhang, Wen ;

Ma, Xinyu ;

Gan, Xinyi ;

Liang, Yuxia ;

Zang, Qijuan ;

Lei, Hao ;

Wei, Yi ;

Zhang, Chaonan ;

Dai, Bingling ;

Zheng, Yan .

APOPTOSIS, 2024, 29 (3-4) :372-392

[3] Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens A Systematic Review and Meta-analysis [J].

Barroso-Sousa, Romualdo ;

Barry, William T. ;

Garrido-Castro, Ana C. ;

Hodi, F. Stephen ;

Min, Le ;

Krop, Ian E. ;

Tolaney, Sara M. .

JAMA ONCOLOGY, 2018, 4 (02) :173-182

[4] Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma [J].

Braun, David A. ;

Bakouny, Ziad ;

Hirsch, Laure ;

Flippot, Ronan ;

Van Allen, Eliezer M. ;

Wu, Catherine J. ;

Choueiri, Toni K. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (04) :199-214

[5] Pan-cancer analysis of UBE2T with a focus on prognostic and immunological roles in lung adenocarcinoma [J].

Cao, Kui ;

Ling, Xiaodong ;

Jiang, Xiangyu ;

Ma, Jianqun ;

Zhu, Jinhong .

RESPIRATORY RESEARCH, 2022, 23 (01)

[6] Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic [J].

Chan, T. A. ;

Yarchoan, M. ;

Jaffee, E. ;

Swanton, C. ;

Quezada, S. A. ;

Stenzinger, A. ;

Peters, S. .

ANNALS OF ONCOLOGY, 2019, 30 (01) :44-56

[7] CD8+ T effector and immune checkpoint signatures predict prognosis and responsiveness to immunotherapy in bladder cancer [J].

Chen, Xingyu ;

Xu, Runshi ;

He, Dong ;

Zhang, Yao ;

Chen, Haotian ;

Zhu, Yuxing ;

Cheng, YaXin ;

Liu, Rui ;

Zhu, Rongrong ;

Gong, Lian ;

Xiao, Mengqing ;

Wang, Zhanwang ;

Deng, Liping ;

Cao, Ke .

ONCOGENE, 2021, 40 (43) :6223-6234

[8] CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment [J].

Di Pilato, Mauro ;

Kfuri-Rubens, Raphael ;

Pruessmann, Jasper N. ;

Ozga, Aleksandra J. ;

Messemaker, Marius ;

Cadilha, Bruno L. ;

Sivakumar, Ramya ;

Cianciaruso, Chiara ;

Warner, Ross D. ;

Marangoni, Francesco ;

Carrizosa, Esteban ;

Lesch, Stefanie ;

Billingsley, James ;

Perez-Ramos, Daniel ;

Zavala, Fidel ;

Rheinbay, Esther ;

Luster, Andrew D. ;

Gerner, Michael Y. ;

Kobold, Sebastian ;

Pittet, Mikael J. ;

Mempel, Thorsten R. .

CELL, 2021, 184 (17) :4512-+

[9] Cancer classification using the Immunoscore: a worldwide task force [J].

Galon, Jerome ;

Pages, Franck ;

Marincola, Francesco M. ;

Angell, Helen K. ;

Thurin, Magdalena ;

Lugli, Alessandro ;

Zlobec, Inti ;

Berger, Anne ;

Bifulco, Carlo ;

Botti, Gerardo ;

Tatangelo, Fabiana ;

Britten, Cedrik M. ;

Kreiter, Sebastian ;

Chouchane, Lotfi ;

Delrio, Paolo ;

Arndt, Hartmann ;

Asslaber, Martin ;

Maio, Michele ;

Masucci, Giuseppe V. ;

Mihm, Martin ;

Vidal-Vanaclocha, Fernando ;

Allison, James P. ;

Gnjatic, Sacha ;

Hakansson, Leif ;

Huber, Christoph ;

Singh-Jasuja, Harpreet ;

Ottensmeier, Christian ;

Zwierzina, Heinz ;

Laghi, Luigi ;

Grizzi, Fabio ;

Ohashi, Pamela S. ;

Shaw, Patricia A. ;

Clarke, Blaise A. ;

Wouters, Bradly G. ;

Kawakami, Yutaka ;

Hazama, Shoichi ;

Okuno, Kiyotaka ;

Wang, Ena ;

O'Donnell-Tormey, Jill ;

Lagorce, Christine ;

Pawelec, Graham ;

Nishimura, Michael I. ;

Hawkins, Robert ;

Lapointe, Rejean ;

Lundqvist, Andreas ;

Khleif, Samir N. ;

Ogino, Shuji ;

Gibbs, Peter ;

Waring, Paul ;

Sato, Noriyuki .

JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10

[10] The prognostic landscape of genes and infiltrating immune cells across human cancers [J].

Gentles, Andrew J. ;

Newman, Aaron M. ;

Liu, Chih Long ;

Bratman, Scott V. ;

Feng, Weiguo ;

Kim, Dongkyoon ;

Nair, Viswam S. ;

Xu, Yue ;

Khuong, Amanda ;

Hoang, Chuong D. ;

Diehn, Maximilian ;

West, Robert B. ;

Plevritis, Sylvia K. ;

Alizadeh, Ash A. .

NATURE MEDICINE, 2015, 21 (08) :938-945

← 1 2 3 4 5 6 →